Introduction. Nevirapine (NVP) resistance may decrease the effectiveness of viral suppression with NVP-based antiretroviral therapy (ART) in women infected with human immunodeficiency virus (HIV) with previous exposure to single-dose NVP. However, the alternative lopinavir-ritonavir-based ART regimen is more expensive. Our objectives were to project the tradeoffs regarding life expectancy, cost, and cost-effectiveness of these ART regimens for NVP-exposed, HIV-infected women in South Africa.
Accompanying this success is a growing amount of evidence that sdNVP induces viral resistance mutations in up to 75% of maternal isolates at 2-8 weeks postpartum [4, 5] . Although early studies using population sequencing techniques reported that these mutations become less prevalent over time, more-sensitive genotypic assays with the ability to detect minority variants have shown persistence of high levels of nevirapine (NVP) resistance [6, 7] .
The clinical significance of drug resistance after receipt of sdNVP remains uncertain. However, recent studies from both Thailand and Botswana report significant decreases in virologic suppression in NVPexposed women, compared with unexposed women [8, 9] . Additional studies are underway to assess the response to antiretroviral therapy (ART) in these women, Figure 1 . Schematic of the model. A simplified model pathway is shown for 2 representative antiretroviral treatment (ART) strategies, nevirapine (NVP)-based ART, and lopinavir-ritonavir-based ART. Postpartum women with a history of single-dose NVP exposure entered the model and were assigned to 1 of 5 strategies. Probabilities of having or not having NVP resistance were determined for the women. Women started ART once their CD4 + cell count reached 200 cells/mm 3 and had a monthly probability of viral suppression and a monthly probability of dying from HIV-related causes (based on CD4 + cell count) or from non-HIV related causes (on the basis of South African life tables [21] ). NVP, nevirapine; NVP-R, nevirapine resistance; VL, viral load.
including the Optimal Combination Therapy After Nevirapine Exposure (OCTANE) study, a randomized, controlled trial that will examine NVP-exposed women's response to NVP-based ART and to more-costly lopinavir-ritonavir-based ART [10] . When this trial is complete, it will provide crucial data on shortterm virologic responses to ART, although it was not designed to assess the long-term implications of treatment choices. Our objectives were to use existing data in a simulation model to project life expectancy, cost, and cost-effectiveness implications of the choice between NVP and lopinavir-ritonavir-based ART regimens for NVP-exposed women in South Africa.
METHODS

Overview
We designed a computer-based model of chronic HIV infection among South African women exposed to sdNVP for the prevention of vertical HIV transmission. We examined the outcomes of 5 strategies used among ART-eligible women: (1) treatment of HIV without ART; (2) treatment with an NVPbased ART regimen; (3) treatment with a lopinavir-ritonavirbased ART regimen; (4) treatment with an NVP-based ART regimen followed by treatment with a lopinavir-ritonavirbased, second-line ART regimen (hereafter referred to as NVPrlopinavir-ritonavir); and (5) treatment with a lopinavirritonavir-based ART regimen followed by treatment with an NVP-based, second-line ART regimen (hereafter referred to as lopinavir-ritonavirrNVP). Model outcomes included mean projected life expectancy, costs, and incremental cost-effectiveness. We applied a modified societal perspective in which patient-time costs were not considered and outcomes of life expectancy and cost were discounted 3% annually [11] .
Decision Analytic Model
The model was structured to simulate the lifetime outcomes of HIV-infected women in South Africa. It was programmed in TreeAge Pro 2005 software (TreeAge Software), and firstand second-order Monte Carlo simulations were performed [12] . The model consisted of clinically relevant health states and transition probabilities between health states [12] .
Women included in the model had prior exposure to sdNVP for prevention of mother-to-child transmission of HIV and a CD4 + cell count at or near the threshold (200 cells/mm 3 ) for initiating ART in South Africa. They were stratified by the presence or absence of NVP resistance (figure 1). Viral load suppression was determined by the efficacy of each regimen, which, in turn, affected CD4 + cell count levels, CD4 + -celldependent survival, and use of health care services.
Strategies
In the no-ART strategy, women received primary care for HIV infection, including cotrimoxazole prophylaxis when the CD4 + cell count was !500 cells/mm 3 . In the ART strategies, women began ART when their CD4 + cell counts decreased to р200 cells/mm 3 , in accordance with South African treatment guidelines [13] . Following these guidelines, the NVP-based regimen consisted of stavudine, lamivudine, and nevirapine, and the lopinavir-ritonavir-based regimen consisted of zidovudine, didanosine, lopinavir, and ritonavir [13] .
Model Parameters
Clinical data. The median age at model entry was 25 years, and the median initial CD4 + cell count was 200 cells/mm 3 , representing a population at or near the threshold to begin ART in South Africa [13, 14] . Prior to initiating ART, CD4 + cell counts decreased at a rate estimated by natural history cohorts (table 1) [15, 16] . Rates of virologic suppression (!50 copies/mL at 24 weeks) for NVP-exposed women on NVPbased regimens were 38.0% and 52.0%, on the basis of the presence or absence of measured NVP resistance [8] , and 65.0% for women receiving lopinavir-ritonavir-based therapy [17] . The rate of virologic failure after initial suppression was estimated from the EuroSIDA study to be 20% over 24 months [18] . Monthly probability of death, including both non-HIVrelated mortality and HIV-related mortality, was derived from Monthly probability of an adverse reaction requiring discontinuation of regimen NVP-based therapy 0.0038 (0.0019-0.0057) [19, 37] lopinavir-ritonavir-based therapy 0.0029 (0.0015-0.0044) [17] Monthly probability of HIV-related mortality, by ART status and CD4 + count [19, 20, 22] Without ART CD4 + cell count of 1500 cells/mm [24, 25] Per month of treatment with a lopinavir-ritonavir-based regimen 78.80 (11.80-98.50) [24, 25] Per month of treatment with cotrimoxazole 2.00 (1.00-3.00) [26] CD4 + cell count (per test) 12.27 (6.14-18.41) [23, 26] HIV load (per test) 38.00 (19.00-76.00) [26] Discount rate per year, % 3 (0-5) [11] NOTE. Range values were considered in sensitivity analyses. ART, antiretroviral therapy; NVP, nevirapine. a CD4 + cell counts at entry followed a triangular distribution bounded by 175 and 225 cells/mm 3 , with a median of 200 cells/mm 3 . b After a monthly probability of death of 0.0132 in the first 3 months after starting ART [19] . c After a monthly probability of death of 0.0520 in the first 3 months after starting ART [19] . d Ages 20-60 years. NOTE. ART, antiretroviral therapy; ICER, incremental cost-effectiveness ratio; lopinavir-ritonavirrNVP, lopinavir-ritonavir-based ART regimen followed by treatment with a NVP-based, second-line ART regimen; NVP, nevirapine; NVPrlopinavir-ritonavir, NVP-based ART regimen followed by treatment with a lopinavir-ritonavir-based, second-line ART regimen; YLS, year of life saved.
a When only 1 line of ART was considered, the incremental cost-effectiveness ratio for lopinavir-ritonavir-based ART was 4400 US dollars. However, when strategies with 2 lines of ART were available and compared with the single-line strategies, the single-line lopinavirritonavir-based ART strategy was weakly dominated by the NVPrlopinavir-ritonavir strategy (it had a higher cost-effectiveness ratio but was less effective than the NVPrlopinavir-ritonavir strategy). b Because the NVPrlopinavir-ritonavir strategy weakly dominated the lopinavir-ritonavir-based ART strategy, its ICER was calculated in comparison with the next less-expensive, nondominated strategy, NVP-based ART.
HIV cohorts in the region [19] [20] [21] [22] . HIV-related mortality was reduced while patients were receiving successful ART [19, 20] . Cost and use data. Data regarding use and costs of inpatient and outpatient services and tuberculosis-related care were obtained from a detailed costing study conducted in South Africa by Cleary et al. [23] . Use by inpatients not receiving ART varied from 0. 22 [24, 25] . The cost of preventive cotrimoxazole therapy was derived from a guide published by international health agencies and was estimated to be $2.00 per month [26] . The cost of laboratory monitoring, including CD4
+ cell count and HIV load testing, was derived from sources in South Africa [23, 26] . Costs prior to 2003 were inflated to 2003 price levels using the gross domestic product deflator for South Africa, and costs in local currency were converted to US dollars on the basis of the mean prevailing exchange rate in 2003 [27, 28] . Prior to initiation of ART, CD4 + cell counts were determined every 6 months. For patients receiving ART, laboratory monitoring included determining CD4 + cell count and viral load every 6 months and chemistry and blood count testing, in accordance with national guidelines [13] .
Assumptions
Each strategy was putatively available to all patients entering the model. We assumed that adherence to antiretroviral medications was similar to adherence observed in trials from which the efficacy parameters were derived. We also assumed that there was no difference in efficacy between the nucleoside reverse-transcriptase inhibitor (NRTI) backbones in the NVPand lopinavir-ritonavir-based regimens specified in the South African treatment guidelines [13] . We applied equal CD4 + cell count increases with NVP-based and lopinavir-ritonavir-based ART over the first 6 months of therapy; thereafter, CD4 + response was governed by the presence or absence of viral load suppression [8, 9] . In the strategies including 2 lines of ART, second-line regimen efficacy was estimated to be 90% of its efficacy as an initial therapy, because of NRTI resistance resulting from first-line treatment failure [29] . We calculated this decrement in efficacy separately for NVP-based therapy, both in the presence and absence of NVP resistance (table 1) .
Sensitivity Analyses
Sensitivity analyses were performed on all model parameters, including the model assumptions mentioned above. In particular, the prevalence of measured NVP resistance was varied over the range of values reported in the literature [4, 30, 31] . Efficacy of virologic suppression, duration of potential antiretroviral efficacy, changes in CD4 + cell count among patients receiving and not receiving ART, and differences in medication costs were varied over clinically and economically relevant ranges. Because a recent clinical study suggested that response to NVP-based regimens in sdNVP-exposed women may improve if they are initiated 16 months postpartum, we also performed a sensitivity analysis examining the impact of this increased efficacy on strategies that include NVP-based ART [6, 7, 9] .
RESULTS
Base Case Analysis
Among patients not receiving ART, a cohort of HIV-infected women in South Africa with a median initial CD4 + cell count of 200 cells/mm 3 had a mean undiscounted life expectancy of 43.7 months (table 2) . This increased to 77.5 months on initiation of NVP-based therapy and to 84.5 months on receipt of a single regimen of lopinavir-ritonavir-based ART. The mean projected lifetime cost for the no-ART strategy was $3170, which increased to $5310 with NVP-based ART and to $7700 with lopinavir-ritonavir-based ART. When only considering strategies in which 1 regimen of ART was used, discounted costs and life expectancies resulted in an incremental costeffectiveness ratio of $800 per year of life saved (YLS) for the NVP-based strategy, compared with the no-ART strategy. Lopinavir-ritonavir-based therapy yielded the highest life expectancy, although its incremental cost-effectiveness ratio, compared with that of NVP-based therapy, was $4400/YLS, which is 15 times that of the NVP-based regimen (compared with the no-ART strategy).
The addition of second-line lopinavir-ritonavir-based therapy to the NVP-based first-line regimen resulted in a mean projected life expectancy of 104.4 months, a gain of 26.9 months over that of NVP-based therapy alone (table 2). The addition of second-line NVP-based therapy to the lopinavirritonavir-based strategy resulted in a life expectancy of 105.4 months, a gain of 20.9 months over that of the lopinavirritonavir-based therapy alone (table 2). Lifetime costs of the NVPrlopinavir-ritonavir strategy were $8580, slightly lower than that of the alternative strategy of lopinavir-ritonavirrNVP ($8900). When strategies containing 2 lines of ART were compared with strategies including only 1 line of ART, the NVPrlopinavir-ritonavir strategy had a cost-effectiveness ratio of $1400. Therefore, the NVPrlopinavir-ritonavir strategy The base-case efficacy of NVP-based therapy was 46% viral suppression at 24 weeks (a weighted average of NVP efficacy in the setting of 39% with NVP resistance and 61% with no NVP resistance). Fifty-two percent efficacy was the rate of viral suppression in the absence of measured NVP resistance, and 68% was the efficacy for women not exposed to NVP [8] . Open and shaded bars indicate life expectancy, and the dotted line indicates the cost-effectiveness ratio of treatment with a lopinavir-ritonavir-based antiretroviral therapy (ART) regimen followed by treatment with a NVP-based, second-line ART regimen (lopinavir-ritonavirrNVP), compared with that of a NVP-based ART regimen followed by treatment with a lopinavir-ritonavir-based, second-line ART regimen (NVPrlopinavirritonavir). C/E, cost-effectiveness; VL, viral load; YLS, year of life saved.
weakly dominated the strategy including only a single line of lopinavir-ritonavir-based ART, because it was more effective and more cost-effective. The lopinavir-ritonavirrNVP strategy had an incremental cost-effectiveness ratio of $2300/YLS, compared with the NVPrlopinavir-ritonavir strategy.
Sensitivity Analyses
Prevalence of NVP resistance and ART efficacy. Reducing measured NVP resistance from 39% to 10% resulted in an increase in life expectancy of 3.4 months for patients receiving NVP-based ART ( figure 2 ). An increase of measured NVP resistance to 75% reduced life expectancy by 4.4 months. Given the uncertainty regarding the efficacy of NVP-based ART after exposure to sdNVP, we varied the efficacy from 50%-125% of its base-case value (figure 2). Life expectancy varied by 11.6 months within a range of efficacy 25% above and below the base case.
Efficacy and duration of ART. We varied the duration of time over which an ART regimen could be effective in the model from the base case of 5 years to 10 years and to an infinite period of potential efficacy. Although this led to an increase in the life expectancy of up to 18.2 additional discounted months with 2 regimen strategies, it had a minimal impact on the costeffectiveness of the strategies (because the incremental change was small) and did not change the rank order of projected outcomes.
We also varied the efficacy of second-line regimens (from the base case first-line efficacy of 90%) to assess the possibility that they may have proportionately different efficacy when used after a failed first-line regimen. A relative decrease of 10%-20% in the efficacy of the second-line NVP regimen decreased the life expectancy associated with the lopinavir-ritonavirrNVP strategy by up to 1.7 months less than that of the NVPrlopinavir-ritonavir strategy. The lopinavir-ritonavirrNVP strategy also became dominated by the NVPrlopinavir-ritonavir strategy, because it was less cost-effective than the NVPrlopinavir-ritonavir strategy when second-line NVP efficacy was reduced. A similar reduction in the efficacy of the second-line lopinavir-ritonavir regimen did not alter the order of strategies on the basis of life expectancy or cost-effectiveness. In addition, varying the probability of virological failure after initial suppression ‫)%01ע(‬ did not change the ordering of outcomes.
Increased Efficacy of NVP-Based ART When Started 16 Months Postpartum
We also examined the effect of increased NVP efficacy when NVP-based ART was initiated 16 months postpartum ( figure 3) . As the efficacy of late (16 months postpartum) NVP was increased, the projected life expectancy associated with the lopinavir-ritonavirrNVP strategy increased to 112.4 months, whereas the outcome of the NVPrlopinavir-ritonavir strategy changed only slightly. The cost-effectiveness ratio for the lopinavir-ritonavirrNVP strategy decreased from its base-case value of $2300/YLS to $1400/YLS, compared with NVPrlopinavirritonavir-based ART.
Medication Cost and Discount Rate
As the cost of lopinavir-ritonavir-based ART was decreased 50% from its base-case value of $78.80 per month to $39.40 per month, lifetime costs of care decreased from $7700 to $6440 but remained higher than the lifetime cost of a single regimen of NVP-based ART, $5310. For the lopinavir-ritonavir-based strategy to be more cost-effective than the NVP-based first-line strategy, the cost of the lopinavir-ritonavir-based regimen had to be reduced to 20% of its base-case cost, or to $15.80 per month. When both first-and second-line therapies were considered, decreasing the cost of lopinavir-ritonavir-based ART by 50% reduced discounted lifetime costs by $700 for both the NVPrlopinavir-ritonavir and the lopinavir-ritonavir ART strategies. Further reducing the cost by 75% (to $19.40 per month) led to discounted lifetime costs of ∼$6030 for strategies including 2 lines of ART, and the cost-effectiveness ratio of the lopinavir-ritonavirrNVP strategy was $760/YLS, which dominated all other ART strategies. Varying the discount rate from 0%-5% did not alter the ordering of strategies in table 2.
DISCUSSION
We developed a simulation model of HIV disease that incorporated the best available natural history, drug resistance, efficacy, and cost data, and used it to project the life expectancy and cost-effectiveness associated with strategies of care for HIVinfected South African women exposed to sdNVP. Compared with non-ART, NVP-based therapy resulted in a per-woman life expectancy increase of 130 months, and lopinavir-ritonavir-based therapy increased life expectancy by 140 months. Although lopinavir-ritonavir-based therapy resulted in the greatest life expectancy, it was substantially more costly and less cost-effective than NVP-based ART when only a single regimen was considered. When added to either NVP or lopinavir-ritonavir-based therapy, second-line therapy increased survival by ∼2 years. Whereas the costs of the NVPrlopinavirritonavir-based strategy were lower than the costs of the lopinavir-ritonavirrNVP strategy, the lopinavir-ritonavirrNVP strategy had a slightly greater life expectancy (1 month), in part because more patients were alive to benefit from the more effective first-line regimen (lopinavir-ritonavir-based therapy).
In sensitivity analyses in which all model parameters were varied, the prevalence of measured NVP resistance had a major impact, in that it increased life expectancy by up to 11.6 months, depending on NVP efficacy. Reducing NVP resistance from 39% to 10%, in line with the Treatment Options Preservation Study (TOPS) (peripartum sdNVP plus zidovudinelamivudine), increased the mean projected life expectancy with 1 regimen of NVP-based ART by 3.4 months [31] . The results were also very sensitive to small changes in the efficacies of second-line regimens. A 10%-20% relative reduction in the efficacy of second-line NVP decreased the life expectancy of the lopinavir-ritonavirrNVP strategy to less than that of the NVPrlopinavir-ritonavir strategy, and it became less cost-effective than the NVPrlopinavir-ritonavir strategy. In addition, increasing NVP efficacy (when NVP was initiated 16 months postpartum) increased survival and improved the cost-effectiveness of the strategy that reserved NVP for a second-line therapy (lopinavir-ritonavirrNVP).
We found that both strategies including 2 lines of ART and the strategy including a single line of NVP-based ART had incremental cost-effectiveness ratios less than the per capita gross domestic product of South Africa ($3290) and would be considered to be "very cost-effective" by the Commission on Macroeconomics in Health [21, 32] . However, reductions in the cost of lopinavir-ritonavir-based ART, in particular, would further reduce the overall costs of care per individual, which may be required to allow for the fullest dissemination of ART in South Africa and in other resource-limited areas [27] .
There are several limitations to this analysis. Data regarding the efficacy of NVP-based ART were derived from 1 observational cohort study, whereas lopinavir-ritonavir efficacy was derived from a single trial. Neither study was performed in South Africa, although both studies are within the realm of reported efficacies from sub-Saharan Africa [33] . Differences in adherence, viral subtypes, level of immunosuppression, and follow-up between these studies, as well as the population we modeled, may have affected the results. However, in sensitivity analyses, we found the ordering of life expectancy and costeffectiveness with different strategies to be generally stable within reasonable ranges of inputs. In addition, we relied on 1 major study for the majority of the cost and use data used in the model [23] . Although this was a detailed study, we had to make several adaptations to use the data in our model, and it is also possible that secular changes in South Africa may have led to changes in some of the costs and uses in the several years since the study was conducted. Over the next few years, it is expected that clinical trials will clarify several of the important parameters in this analysis, principally, the response to NVP and lopinavir-ritonavir-based regimens after exposure to sdNVP [10] . We believe that modeling analyses and clinical trials conducted in parallel provide important and complementary information. Additional modeling efforts should be undertaken using data from these clinical studies to better calibrate and validate findings of the current study and to project outcomes beyond those reported in the clinical trials. In addition, as more data become available on the efficacy of later NVP-based therapy (16 months postpartum), further analyses could address the optimal timing of ART depending on the CD4 + cell count in the peripartum period. Decisions regarding ART for women exposed to sdNVP are of critical importance in South Africa. This analysis suggests that drug resistance caused by exposure to sdNVP may substantially decrease the life expectancy of women starting NVPbased regimens. When only a single line of ART was used, lopinavir-ritonavir-based therapy resulted in a longer projected survival than did NVP-based ART, although it was less costeffective. The use of 2 lines of therapy, starting with lopinavirritonavir-based therapy and following it with NVP-based therapy, was associated with the longest projected life expectancy and was only slightly more expensive. This strategy became more attractive when the efficacy of NVP-based therapy was assumed to increase if it was initiated 16 months after exposure to sdNVP, although the superiority of the lopinavir-ritonavirrNVP strategy was sensitive to small decreases in the efficacy of second-line NVP-based therapy. On the basis of currently available data, the sequential regimen of lopinavir-ritonavirrNVP appears to be the optimal ART strategy for the clinical management of South African women in need of ART.
